BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16273217)

  • 1. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
    Manara MC; Perdichizzi S; Serra M; Pierini R; Benini S; Hattinger CM; Astolfi A; Bagnati R; D'Incalci M; Picci P; Scotlandi K
    Int J Oncol; 2005 Dec; 27(6):1605-16. PubMed ID: 16273217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
    Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
    Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
    Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
    Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
    Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
    Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells.
    Scotlandi K; Avnet S; Benini S; Manara MC; Serra M; Cerisano V; Perdichizzi S; Lollini PL; De Giovanni C; Landuzzi L; Picci P
    Int J Cancer; 2002 Sep; 101(1):11-6. PubMed ID: 12209582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
    Erba E; Bergamaschi D; Bassano L; Ronzoni S; Di Liberti G; Muradore I; Vignati S; Faircloth G; Jimeno J; D'Incalci M
    Br J Cancer; 2000 May; 82(10):1732-9. PubMed ID: 10817511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.
    Garofalo C; Mancarella C; Grilli A; Manara MC; Astolfi A; Marino MT; Conte A; Sigismund S; Carè A; Belfiore A; Picci P; Scotlandi K
    Mol Endocrinol; 2012 Sep; 26(9):1603-16. PubMed ID: 22798295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells.
    Strammiello R; Benini S; Manara MC; Perdichizzi S; Serra M; Spisni E; Picci P; Scotlandi K
    Horm Metab Res; 2003; 35(11-12):675-84. PubMed ID: 14710346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A functional, new short isoform of death receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms.
    Picarda G; Surget S; Guiho R; Téletchéa S; Berreur M; Tirode F; Pellat-Deceunynck C; Heymann D; Trichet V; Rédini F
    Mol Cancer Res; 2012 Mar; 10(3):336-46. PubMed ID: 22258765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells.
    Scotlandi K; Maini C; Manara MC; Benini S; Serra M; Cerisano V; Strammiello R; Baldini N; Lollini PL; Nanni P; Nicoletti G; Picci P
    Cancer Gene Ther; 2002 Mar; 9(3):296-307. PubMed ID: 11896447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
    Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription of the multidrug resistance gene MDR1: a therapeutic target.
    Scotto KW; Johnson RA
    Mol Interv; 2001 Jun; 1(2):117-25. PubMed ID: 14993331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
    Benini S; Manara MC; Cerisano V; Perdichizzi S; Strammiello R; Serra M; Picci P; Scotlandi K
    Int J Cancer; 2004 Jan; 108(3):358-66. PubMed ID: 14648701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
    Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
    Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M; Jimeno J
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
    Poindessous V; Koeppel F; Raymond E; Comisso M; Waters SJ; Larsen AK
    Clin Cancer Res; 2003 Jul; 9(7):2817-25. PubMed ID: 12855662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
    Subbiah V; Naing A; Brown RE; Chen H; Doyle L; LoRusso P; Benjamin R; Anderson P; Kurzrock R
    PLoS One; 2011 Apr; 6(4):e18424. PubMed ID: 21494688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.
    Li WW; Takahashi N; Jhanwar S; Cordon-Cardo C; Elisseyeff Y; Jimeno J; Faircloth G; Bertino JR
    Clin Cancer Res; 2001 Sep; 7(9):2908-11. PubMed ID: 11555609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.
    Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
    Mol Oncol; 2020 May; 14(5):1101-1117. PubMed ID: 32115849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.
    Martinez EJ; Corey EJ; Owa T
    Chem Biol; 2001 Dec; 8(12):1151-60. PubMed ID: 11755394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.